RBC Capital Downgrades Iterum Therapeutics (ITRM) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts ITRM Hot Sheet
Price: $0.03 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 39 | New: 7
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 39 | New: 7
Join SI Premium – FREE
RBC Capital analyst Gregory Renza downgraded Iterum Therapeutics (NASDAQ: ITRM) from Outperform to Sector Perform with a price target of $2.00 (from $7.00).
For an analyst ratings summary and ratings history on Iterum Therapeutics click here. For more ratings news on Iterum Therapeutics click here.
Shares of Iterum Therapeutics closed at $1.86 yesterday.
You May Also Be Interested In
- Goldman Sachs Downgrades Luk Fook Holdings International Ltd. (590:HK) (LKFLF) to Sell
- Goldman Sachs Upgrades Chow Tai Fook Jewellery Group Ltd. (1929:HK) (CJEWF) to Buy
- Pidilite Industries Ltd (PIDI:IN) PT Lowered to INR1,635 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
